Steven V Molinski1, Tanja Gonska2, Ling Jun Huan3, Berivan Baskin4, Ibrahim A Janahi5, Peter N Ray6, Christine E Bear7. 1. 1] Programme in Molecular Structure and Function, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada [2] Department of Biochemistry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. 2. 1] Programme in Physiology and Experimental Medicine, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada [2] Department of Pediatrics, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. 3. Programme in Molecular Structure and Function, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada. 4. Department of Immunology, Genetics and Pathology, The Rudbeck Laboratory, Uppsala University, Uppsala, Sweden. 5. Section of Pediatric Pulmonology, Department of Pediatrics, Hamad Medical Corporation, Doha, Qatar. 6. 1] Programme in Genetics and Genomic Biology, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada [2] Department of Molecular Genetics, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. 7. 1] Programme in Molecular Structure and Function, Research Institute, Hospital for Sick Children, Toronto, Ontario, Canada [2] Department of Biochemistry, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada [3] Department of Physiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Abstract
PURPOSE: The purpose of this study was to determine the molecular consequences of the variant c.3700 A>G in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, a variant that has been predicted to cause a missense mutation in the CFTR protein (p.Ile1234Val). METHODS: Clinical assays of CFTR function were performed, and genomic DNA from patients homozygous for c.3700 A>G and their family members was sequenced. Total RNA was extracted from epithelial cells of the patients, transcribed into complementary DNA, and sequenced. CFTR complementary DNA clones containing the missense mutation p.Ile1234Val or a truncated exon 19 (p.Ile1234_Arg1239del) were constructed and heterologously expressed to test CFTR protein synthesis and processing. RESULTS: In vivo functional measurements revealed that the individuals homozygous for the variant c.3700 A>G exhibited defective CFTR function. We show that this mutation in exon 19 activates a cryptic donor splice site 18 bp upstream of the original donor splice site, resulting in deletion of six amino acids (r.3700_3717del; p.Ile1234_Arg1239del). This deletion, similar to p.Phe508del, causes a primary defect in folding and processing. Importantly, Lumacaftor (VX-809), currently in clinical trial for cystic fibrosis patients with the major cystic fibrosis-causing mutation, p.Phe508del, partially ameliorated the processing defect caused by p.Ile1234_Arg1239del. CONCLUSION: These studies highlight the need to verify molecular and clinical consequences of CFTR variants to define possible therapeutic strategies.
PURPOSE: The purpose of this study was to determine the molecular consequences of the variant c.3700 A>G in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, a variant that has been predicted to cause a missense mutation in the CFTR protein (p.Ile1234Val). METHODS: Clinical assays of CFTR function were performed, and genomic DNA from patients homozygous for c.3700 A>G and their family members was sequenced. Total RNA was extracted from epithelial cells of the patients, transcribed into complementary DNA, and sequenced. CFTR complementary DNA clones containing the missense mutation p.Ile1234Val or a truncated exon 19 (p.Ile1234_Arg1239del) were constructed and heterologously expressed to test CFTR protein synthesis and processing. RESULTS: In vivo functional measurements revealed that the individuals homozygous for the variant c.3700 A>G exhibited defective CFTR function. We show that this mutation in exon 19 activates a cryptic donor splice site 18 bp upstream of the original donor splice site, resulting in deletion of six amino acids (r.3700_3717del; p.Ile1234_Arg1239del). This deletion, similar to p.Phe508del, causes a primary defect in folding and processing. Importantly, Lumacaftor (VX-809), currently in clinical trial for cystic fibrosis patients with the major cystic fibrosis-causing mutation, p.Phe508del, partially ameliorated the processing defect caused by p.Ile1234_Arg1239del. CONCLUSION: These studies highlight the need to verify molecular and clinical consequences of CFTR variants to define possible therapeutic strategies.
Authors: Jeffrey B S Gaither; Grant E Lammi; James L Li; David M Gordon; Harkness C Kuck; Benjamin J Kelly; James R Fitch; Peter White Journal: Gigascience Date: 2021-04-05 Impact factor: 6.524
Authors: P Andrew Chong; Patrick J Farber; Robert M Vernon; Rhea P Hudson; Anthony K Mittermaier; Julie D Forman-Kay Journal: J Biol Chem Date: 2015-07-06 Impact factor: 5.157
Authors: Melissa Lee; Patrick Roos; Neeraj Sharma; Melis Atalar; Taylor A Evans; Matthew J Pellicore; Emily Davis; Anh-Thu N Lam; Susan E Stanley; Sara E Khalil; George M Solomon; Doug Walker; Karen S Raraigh; Briana Vecchio-Pagan; Mary Armanios; Garry R Cutting Journal: Am J Hum Genet Date: 2017-05-04 Impact factor: 11.025
Authors: Robert M Vernon; P Andrew Chong; Hong Lin; Zhengrong Yang; Qingxian Zhou; Andrei A Aleksandrov; Jennifer E Dawson; John R Riordan; Christie G Brouillette; Patrick H Thibodeau; Julie D Forman-Kay Journal: J Biol Chem Date: 2017-06-27 Impact factor: 5.157
Authors: Carleen M Sabusap; Wei Wang; Carmel M McNicholas; W Joon Chung; Lianwu Fu; Hui Wen; Marina Mazur; Kevin L Kirk; James F Collawn; Jeong S Hong; Eric J Sorscher Journal: JCI Insight Date: 2016-09-08
Authors: Steven V Molinski; Saumel Ahmadi; Wan Ip; Hong Ouyang; Adriana Villella; John P Miller; Po-Shun Lee; Kethika Kulleperuma; Kai Du; Michelle Di Paola; Paul Dw Eckford; Onofrio Laselva; Ling Jun Huan; Leigh Wellhauser; Ellen Li; Peter N Ray; Régis Pomès; Theo J Moraes; Tanja Gonska; Felix Ratjen; Christine E Bear Journal: EMBO Mol Med Date: 2017-09 Impact factor: 12.137
Authors: Puay-Wah Phuan; Peter M Haggie; Joseph A Tan; Amber A Rivera; Walter E Finkbeiner; Dennis W Nielson; Merlin M Thomas; Ibrahim A Janahi; Alan S Verkman Journal: J Cyst Fibros Date: 2020-07-14 Impact factor: 5.482
Authors: Matthew Coghlan; Elizabeth Richards; Sadiq Shaik; Pablo Rossi; Ramesh Babu Vanama; Saumel Ahmadi; Christelle Petroz; Mark Crawford; Jason T Maynes Journal: Sci Rep Date: 2018-03-27 Impact factor: 4.379